Track market-moving stories before they get noisy

Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, welcomes the decision of the Unified Patent Court (“UPC”) finding that aligner systems incorporating Angelalign’s Torque Ridges feature infringe Align’s European Patent EP 2 237 738 B1, which relates to Align’s Power Ridge® technology.

In August 2025, Align initiated patent infringement proceedings against several companies within the Angelalign Technology, Inc. corporate group (“Angel”) (Hong Kong Stock Exchange: 6699.HK) in multiple jurisdictions, including before the UPC, which covers participating European Union member states.

On October 16, 2026, the Paris Local Division of the UPC ruled that aligner systems incorporating Angel’s Torque Ridges feature infringe Align’s patent. The Court rejected Angel’s challenges to the validity of the patent, issued an injunction requiring Angel to recall and destroy infringing products, ordered Angel to pay damages to Align, and granted Align other relief. Angel must cease offering infringing aligner systems incorporating Torque Ridges in Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Slovenia, and Sweden. The decision is subject to appeal.

Commenting on the UPC decision, Arthur S. Hsieh, Align Technology vice president, Deputy General Counsel, Intellectual Property & Licensing, said, “The ruling represents a significant victory for Align and underscores the importance of protecting the innovations resulting from Align’s substantial and sustained investment in research and development. Angel has sought to downplay the impact of the ruling by emphasizing that Angel recently discontinued Torque Ridges in Europe and introduced a different feature called ‘Pressure Points.’ This should not obscure the significance of the Court’s decision: Angel’s Torque Ridges were found to infringe Align’s patented technology, and Angel has publicly stated that it will comply with the Court’s ruling, which requires Angel to recall and destroy infringing products, pay damages to Align, and take other remedial actions. Similarly, Angel’s characterization of Pressure Points as an “upgrade” or “next generation” of Torque Ridges should not be understood to establish that the two technologies are technically equivalent or that Pressure Points provide an equivalent alternative to Torque Ridges. Angel’s own public materials describe Pressure Points as based on the longstanding use of “hand-made dimples” to apply targeted forces to teeth. Align does not view Angel’s Pressure Points as a technological upgrade to, or an equivalent replacement for, the ridge-based technology at issue in the UPC proceeding.”

Align’s Power Ridge® technology is designed to apply targeted forces to improve root torque control and support predictable tooth movement. The Power Ridge feature remains available as an integral part of the Invisalign® System, providing doctors with differentiated technology to support high-quality patient care.

Align has not taken a public position on whether Angel’s Pressure Points implicate Align’s intellectual property rights. Align will continue to evaluate products and technologies offered by Angel and other market participants and will take appropriate action when necessary to protect its innovations and intellectual property.

The October 16 decision follows other recent developments in Align’s global patent enforcement actions against Angel. In February 2026, the UPC issued a preliminary injunction requiring Angel to cease infringement of Align’s patented ClinCheck® Live Update technology. That decision was subsequently upheld by the UPC Court of Appeal, and proceedings on the merits remain ongoing. In July 2026, the U.S. International Trade Commission (“ITC”) conducted an evidentiary hearing concerning five patents asserted by Align against Angel. Align expects an initial determination regarding the merits of its claims in November 2026. In August 2026, the Jinan Intermediate People's Court in China issued a first-instance judgment finding that Angel's use of its MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system to generate A7 and A7 Speed premolar extraction treatment solutions infringes Align's patent rights. The court further found that aligner products manufactured and sold using the accused technology also infringe. Angel has appealed the Jinan Court’s decision. Align continues to pursue additional patent infringement actions against Angel in China.

Align remains committed to advancing orthodontic treatment through differentiated technologies backed by decades of research, engineering, clinical experience, and investment, and to vigorously protecting the intellectual property underlying those innovations.

Align’s Cutting-Edge Global Operations

As a global leader in digital orthodontics and restorative dentistry with nearly 23.5 million Invisalign® patients treated worldwide, Align continues to transform the orthodontic industry through its global operations, advanced manufacturing capabilities, and doctor-directed treatment planning. Annually, Align invests over $300M in technology to give patients of all ages access to the smiles they want and deserve through Invisalign-trained doctors.

Align’s operations span the Americas, EMEA, and APAC regions, with clinical treatment planning centers in Costa Rica, Poland, China (Chengdu), Spain, France, Germany, and Japan. The company’s global aligner manufacturing operations includes world-class facilities in Juarez, Mexico; Wroclaw, Poland; and Ziyang, China; Vienna, Austria; San Jose, CA; and a new aligner manufacturing facility coming online in 2027 in Hyderabad, India, together forming the backbone of the world’s largest 3D printing network for dental aligners (appliances).

Align’s investments in global operations are designed to bring its facilities closer to doctor-customers and their patients. In Mexico, the Juarez facility serves as a strategic node in Align’s global supply chain, enabling fast and cost-effective delivery of aligners to customers in the U.S., Canada, Latin America, and beyond. In China, the Chengdu treatment planning center and Ziyang manufacturing facility are central to Align’s long-term investment strategy for China, supporting the local economy and one of its fastest-growing markets by helping Chinese doctors provide millions of Chinese consumers access to high-quality orthodontic care. Wroclaw, Poland is the operations hub for Align’s EMEA business, bringing operations and support closer to the more than 63,000 Invisalign-trained doctors in the region.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 302.0 thousand doctor-customers and are key to accessing Align’s 600-million-consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 23.5 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and labs/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.

Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261016990429/en/

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Baird analyst Jeff Johnson downgraded Envista Holdings Corp (NYSE:NVST) from Outperform to Neutral and cut the price target from $34 to $26. Envista closed at $22.82 on Wednesday. See how other analysts view this stock. Keybanc analyst John Vinh downgraded Cirrus Logic Inc (NASDAQ:CRUS) from Overweight to Equal-Weight. Cirrus Logic shares closed at $108.34 on Wednesday. See how other analysts view this stock. Goldman Sachs analyst Ronald Keung downgraded ZTO Express (Cayman) Inc (NYSE:ZTO) from Buy to Neutral and slashed the price target from $25 to $22. ZTO Express closed at $20.36 on Wednesday. See how other analysts view this stock. Baird analyst Jeff Johnson downgraded Align Technology Inc (NASDAQ:ALGN) from Outperform to Neutral and cut the price target from $218 to $162. Align Technology shares closed at $144.44 on Wednesday. See how other analysts view this stock. Goldman Sachs analyst Neil Mehta downgraded Par Pacific Holdings Inc (NYSE:PARR) from Buy to Neutral and raised the price target from $90 to $94. Par Pacific closed at $88.67 on Wednesday. See how other analysts view this stock. Considering buying ALGN stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Wall Street kicked off the first full week of Q4 2026 with a flurry of bold analyst moves, including a sweeping Microsoft upgrade and a brutal Align Technology target slash. Find out which names got upgraded, downgraded, or freshly initiated…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Pre-Market Stock Futures:

Futures are trading lower as we get ready for the first full week of trading for the fourth quarter of 2026 after an outstanding Friday, which saw all of the major indices finish the day higher, after the non-farm payroll numbers for September came in well below estimates before the open and caused a large Treasury sell-off that countered Thursday’s buying spree.

On Friday,  the Nasdaq stormed to an intraday all-time high before closing at 27,190, up 1.19%, while the small-cap Russell 2000 also finished strong, up 0.94% at 2,932. The S&P 500 closed the session at 7,7722 up 0.73%, while the Dow Jones Industrials closed the week at 51,176, up 0.49%. Wall Street strategists will watch the ISM Services results early in the week, a major gauge of economic strength, plus the FOMC notes on Wednesday, which will give investors color on why the Fed raised rates in September and what it may do at its late-month October meeting.

Treasury Bonds: After a huge selling spree following the non-farm payroll results early Friday, some buyers stepped in, but by the close yields were higher across the Treasury curve except for the shortest T-bill maturities as the sellers returned in force by the afternoon. The very weak non-farm payrolls report signaled to many that a rate hike at the October meeting may be totally off the board. The 30-year bond closed Friday at 5.62%, while the 10-year note was last seen at 5.27%. 

Oil and Gas: The energy complex had a fairly mild end to the week as the G7 announced it would release 100 million barrels from reserves to counter the diesel fuel crisis in Europe and worldwide. Meanwhile, oil from Iran started flowing to Tajikistan despite U.S. sanctions, which could prove interesting. When the markets closed, Brent Crude finished the session at $102.80, up 0.47%, while West Texas Intermediate closed the day at $91.26, down 1.72%. Natural gas finished the week strong, closing at $3.05, up 2.73%.

Gold: After a solid week for the bullion, the sellers showed up on Friday. A stronger dollar and initially weak jobs data drew buyers early in the session, but that reversed; by the close, gold was last seen at $4,139, down 0.88%, while Silver closed at $60.27, down 1%. 

Crypto: Cryptocurrency markets were highly volatile on Friday, surging early in the morning before erasing most gains after the U.S. jobs report. Bitcoin spiked above $87,200 early Friday, propelled by short covering, a brand-new $113,000 Citigroup price target, and a bullish “golden cross” chart pattern. However, as gold and equities pulled back, broader crypto markets faced strong selling pressure later in the day, dragging Bitcoin back to around $84,490 by the market close. At 8 AM EDT, Bitcoin was trading at $86,120, while Ethereum was quoted at $2,718.

24/7 Wall St. reviews dozens of analyst research reports every day to identify fresh investment ideas for investors and traders alike. These daily analyst notes include recommendations on stocks to buy, sell, or avoid, as well as new coverage initiations. Important reminder: No single analyst report should ever be the sole basis for buying or selling a stock.

Here are some of the top Wall Street analyst upgrades, downgrades, and initiations from Monday, October 5, 2026. 

Upgrades: Estee Lauder (NYSE: EL | EL Price Prediction) was upgraded to Outperform from Sector Perform at Barclays, which raised the price target for the stock to $108 from $97. Harley-Davidson (NYSE: HOG) was raised to Buy from Neutral at Citigroup, which bumped the target price to $33 from $31. Microsoft Corporation (NASDAQ: MSFT) was upgraded to Buy from Hold at Melius Research, which has a $665 target price for the technology giant. Ryder System (NYSE: R) was upgraded to Overweight from Neutral at JPMorgan, which nudged the target price to $298 from $296. Wells Fargo & Company  (NYSE: WFC) was upgraded to Overweight from Equal Weight at Morgan Stanley, with an unchanged $102 target price. Downgrades: Align Technology (NASDAQ: ALGN) was downgraded to In Line from Outperform at Evercore ISI, which slashed the target price for the shares to $155 from $220. AutoNation (NYSE: AN) was downgraded to Equal Weight from Overweight with a $175 target price. Group 1 Automotive (NYSE: GPI) was downgraded to Underweight from Equal Weight at Morgan Stanley, with a $232 target price. HubSpot (NASDAQ: HUBS) was cut to Market Perform from Outperform at Raymond James, without a target price. Mosaic Company (NYSE: MOS) was downgraded to Sector Perform from Outperform at RBC Capital, which trimmed the target price to $25 from $27. Initiations: nVent Electric (NYSE: NVT) was initiated with an Outperform rating at BMO Capital, which has a $212 target price for the shares. Revolution Medicines (NASDAQ: RVMD) was resumed with an Outperform rating at Leerink, which has a $288 target price. Samsara (NYSE: IOT) was initiated with a Buy rating at Jefferies, with a $50 target price. Vertiv Holdings(NYSE: VRT) was initiated with an Outperform rating at BMO Capital, with a $329 target price. 
Vylor (NASDAQ: VYLR) was initiated with a Buy rating at Vertical Research with a $74 target price. Contact [email protected] for any questions or corrections.

Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among the rest: earnings.

We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.

Now that we know how important earnings and earnings surprises are, it's time to show investors how to take advantage of these events to boost their returns by utilizing the Zacks Earnings ESP filter.

The Zacks Earnings ESP, ExplainedThe Zacks Expected Surprise Prediction, or ESP, works by locking in on the most up-to-date analyst earnings revisions because they can be more accurate than estimates from weeks or even months before the actual release date. The thinking is pretty straightforward: analysts who provide earnings estimates closer to the report are likely to have more information.

Now that we understand the basic idea, let's look at how the Expected Surprise Prediction works. The ESP is calculated by comparing the Most Accurate Estimate to the Zacks Consensus Estimate, with the percentage difference between the two giving us the Zacks ESP figure.

In fact, when we combined a Zacks Rank #3 (Hold) or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time. Perhaps most importantly, using these parameters has helped produce 28.3% annual returns on average, according to our 10 year backtest.

Stocks with a ranking of #3 (Hold), or 60% of all stocks covered by the Zacks Rank, are expected to perform in-line with the broader market. Stocks with rankings of #2 (Buy) and #1 (Strong Buy), or the top 15% and top 5% of stocks, respectively, should outperform the market; Strong Buy stocks should outperform more than any other rank.

Should You Consider Align Technology?The final step today is to look at a stock that meets our ESP qualifications. Align Technology (ALGN - Free Report) earns a #3 (Hold) 26 days from its next quarterly earnings release on October 28, 2026, and its Most Accurate Estimate comes in at $2.81 a share.

ALGN has an Earnings ESP figure of +1.23%, which, as explained above, is calculated by taking the percentage difference between the $2.81 Most Accurate Estimate and the Zacks Consensus Estimate of $2.78. Align Technology is one of a large database of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

ALGN is part of a big group of Medical stocks that boast a positive ESP, and investors may want to take a look at Iovance Biotherapeutics (IOVA - Free Report) as well.

Iovance Biotherapeutics is a Zacks Rank #3 (Hold) stock, and is getting ready to report earnings on November 5, 2026. IOVA's Most Accurate Estimate sits at -$0.07 a share 34 days from its next earnings release.

For Iovance Biotherapeutics, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of -$0.09 is +22.22%.

ALGN and IOVA's positive ESP metrics may signal that a positive earnings surprise for both stocks is on the horizon.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the launch of SHIFT Happens, a new consumer campaign designed to help Invisalign-trained doctors connect with and educate adult consumers about lifelong tooth movement and explain the be.

Why These 3 Tech Stocks Could Be the Best Opportunities You're OverlookingAlign Technology NASDAQ: ALGN sees continued growth potential for Invisalign clear aligners in the United States and internationally despite a challenging consumer environment, Chief Financial Officer John Morici said during a Baird investor conference.

Morici said inflation and patient reluctance to begin treatment have weighed on the orthodontics market over roughly the past 18 months. Those pressures can influence how orthodontists and general practitioners invest in their practices and whether patients move forward with treatment.

Get Align Technology alerts:

Buy the Dip? These Earnings Misses Offer Long-Term UpsideStill, he said the company sees substantial room to replace traditional wires-and-brackets treatments with clear aligners. Morici said approximately 75% of combined teen and adult orthodontic cases in North America are still performed using wires and brackets.

“We have a huge opportunity to grow in U.S., just like the rest of the world, to get clear aligners, to have Invisalign,” Morici said.

Product and Financing Efforts Target Conversion MarketBeat Week in Review: 12/25 - 12/29Morici said Align is seeking to help doctors compete with the upfront economics of traditional orthodontic treatment by offering products with fewer included refinements. Those offerings can lower initial costs for practices compared with more comprehensive products, while giving doctors the option to pay for refinements later if needed.

The company is also emphasizing consumer financing options, which Morici described as increasingly important in converting potential patients. Align has worked with Healthcare Finance Direct and other lenders, he said, while also seeing financing become a larger consideration in Europe and other international markets.

In addition to financing, Morici said visualization tools that show prospective patients what their teeth may look like after treatment can support conversion at orthodontic and general-practice offices.

Align’s no-AA, or no-refinement, product initially launched with certain dental service organizations, or DSOs, in the U.S. and is being introduced to retail doctors. Morici said adoption has been favorable, although doctors must plan cases carefully when using products designed for limited or no refinements.

He said the strategy is intended to expand utilization by helping doctors choose Invisalign in situations where they might otherwise use wires and brackets because of a lower lab bill. While the company may collect less cash upfront on some cases, Morici said doctors using the products have tended to perform more Invisalign cases.

Align said no-refinement products can support gross-margin improvement by reducing the number of refinements in the product mix. The company is also offering touch-up and lower-stage products intended to meet different clinical and pricing needs. Morici said Align’s focus is primarily on converting wires-and-brackets cases rather than simply taking share from other clear-aligner providers. International Growth and New Product Rollouts Morici said international markets remain underpenetrated and have responded well to newer products, including Invisalign Personalization Experience, or IPE, and touch-up offerings. Align has expanded certain products into Europe and Asia-Pacific, including DSP in Asia during the second half of the year, he said.

He noted that 55% of Align’s business is outside North America and said that business has been growing at double-digit rates. India, Southeast Asia and Brazil have shown strong growth following investments in sales and marketing resources, according to Morici.

Within North America, he said DSOs account for about one-third of the company’s regional business and have also been growing at double-digit rates. The company’s key area of focus is North American retail business, which Morici characterized as roughly 30% of Align’s overall operations.

When discussing the company’s outlook, Morici said Align bases its guidance on recent business trends, current market conditions and product introductions rather than solely on year-over-year comparisons. He said Align’s first-half case volume rose about 7% on average, while its second-half guidance implied approximately 5% to 6% year-over-year volume growth.

China Volume-Based Procurement Could Expand Access Morici also addressed China’s orthodontic volume-based procurement, or VBP, process. Align currently operates predominantly in China’s private market, but Morici said the company expects the effects of VBP on public providers to extend to private pricing over time.

He said about 90% of orthodontic cases in China are performed with wires and brackets, while clear aligners remain a relatively small part of the market. Align expects its portfolio, ranging from comprehensive to more moderate and lower-stage cases, to allow it to compete in the VBP environment.

While pricing pressure could emerge, Morici said Align could gain volume by reaching doctors who previously did not use its products. He also pointed to the company’s manufacturing and treatment-planning operations in China as potential cost offsets.

The VBP process could create opportunities for Align to participate in public hospitals where it has had less exposure, he said. The company would evaluate tenders based on whether pricing, incremental revenue and costs make economic sense.

Margin Framework and Research Spending Morici said Align is pursuing productivity initiatives alongside volume growth, including shifting some manufacturing closer to regional markets to reduce freight costs and delivery times. He also cited a planned India facility focused on serving the Indian market, which he said could improve cycle times while reducing customs and duty costs.

He reiterated the company’s focus on structural profitability improvements, including product mix and operational programs. Morici said Align has discussed about 100 basis points of operating-margin improvement for the current year and at least 100 basis points for the following year.

On research and development, Morici said spending should gain leverage as products move from research into development and commercialization. He said investments in direct fabrication, resin technology and the iTero Lumina platform have increasingly shifted toward development, though the company intends to continue investing in technology and innovation.

About Align Technology (NASDAQ:ALGN)Align Technology, Inc NASDAQ: ALGN is a global medical device company that designs, manufactures and markets products used in orthodontics and digital dentistry. Its best-known product is the Invisalign system, a series of clear, removable aligners intended to gradually straighten teeth and address certain orthodontic conditions under the supervision of dental professionals.

The company also develops digital dentistry technologies, including iTero intraoral scanners and related software, which create digital impressions and support orthodontic, restorative and implant treatment planning.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Align Technology Right Now?Before you consider Align Technology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Align Technology wasn't on the list.

While Align Technology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Key Takeaways Align Technology broadened Invisalign options, with teen and growing-patient starts up 7.2% year over year.ALGN uses DSO partnerships and digital campaigns to support digital dentistry adoption and volume growth.ALGN's iTero placements hit records, with scans up 16%, despite weak capital-equipment spending. Align Technology (ALGN - Free Report) is well-positioned for growth in the upcoming quarters as it continues to broaden the clinical reach of the Invisalign portfolio beyond traditional adult and teen alignment. The company is focused on increasing adoption of digital dentistry through DSO relationships, doctor support programs and consumer engagement. The iTero business is gaining traction, supported by record new-doctor placements and higher scan volumes. However, weak capital-equipment spending and currency movements continue to pose risks for Align Technology’s results.

Over the past year, this Zacks Rank #3 (Hold) stock has gained 15.1% compared with the 18.2% rise of the industry and the S&P 500 composite’s 16.5% growth.

The renowned medical device company has a market capitalization of $10.80 billion. ALGN projects a long-term estimated earnings growth rate of 10% compared with the 9.3% growth of the industry. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.4%.

Let’s delve deeper.

Upsides for ALGN StockInvisalign Business Expansion: Align Technology’s Invisalign Palatal Expander, Invisalign First and Invisalign with Mandibular Advancement featuring Occlusal Blocks broaden treatment options for growing patients and more complex cases. The company expanded its Palatal Expander into key EMEA and APAC markets. The product launched commercially in India, Malaysia and Turkey, received a CE mark covering most of Europe and secured regulatory approval in China. Invisalign with Mandibular Advancement featuring Occlusal Blocks also expanded into India, Malaysia, the Philippines and Thailand, adding to its existing availability in the United States, Canada, Australia and New Zealand.

In the second quarter, teen and growing-patient treatment starts increased 7.2% year over year to 240,000 cases, led by China, Japan, Turkey, India and Brazil. Beyond orthodontics, Align Technology is linking clear aligner treatment with restorative care. The company expanded its Advanced Restorative Treatment initiative, and in the second quarter, exocad launched ART software that combines tooth alignment with restorative treatment planning.

Image Source: Zacks Investment Research

Strategic Alliances: Align Technology is leaning on dental service organizations, doctor-support programs and consumer outreach to broaden adoption of digital dentistry. The company has established relationships with DSOs, particularly in the United States, and had previously expanded partnerships with groups such as Smile Doctors and Heartland Dental. The strategy remained relevant in the second quarter of 2026, when DSO Clear Aligner volume grew at a double-digit rate year over year.

Align Technology has used digital campaigns across TikTok, Instagram, YouTube, Snapchat and WeChat, along with regional campaigns in Japan, India, Malaysia and Europe. Management’s second-half 2026 outlook assumes continued execution of these customer-focused initiatives, with financing, DSP, clinical education and DSO collaboration cited as areas showing early traction.

iTero in Focus: The company’s iTero intraoral scanners and exocad CAD/CAM software remain central to its digital dentistry strategy because each scan can connect diagnostics, treatment planning, restorative workflows and Clear Aligner conversion. The scanner business is shifting toward lower-cost configurations, certified pre-owned systems, leases and rentals, which reduce upfront revenues but lower the acquisition barrier for practices.

During the second quarter, scanner placements to new doctors reached a record level, increasing at a double-digit rate year over year, while the active installed base grew about 11%. More than 12.4 million restorative, wellness and orthodontic scans were completed in the quarter, up 16% year over year. Exocad revenues also increased at a double-digit rate.

What Ails ALGN Stock?Macroeconomic Concerns: Align Technology continues to operate in an uneven demand environment because orthodontic treatment and dental capital equipment purchases are sensitive to consumer and practice spending. Management cited softer retail demand and said its outlook does not assume better macroeconomic conditions. The capital equipment market remained weak as higher interest rates and economic uncertainty affected scanner purchasing decisions. This contributed to a 10.8% year-over-year decline in Systems and Services revenues during the second quarter.

Currency Volatility: Foreign exchange remains a recurring source of volatility because a sizable portion of Align Technology’s business is generated outside the United States. In the second quarter of 2026, currency movements reduced gross margin by about 0.8 points and operating margin by about 1.4 points year over year. Management expects the full-year 2026 revenue benefit from foreign exchange to trend toward approximately 100 basis points, but quarter-to-quarter currency changes can still affect ASPs, margins and reported earnings. 

ALGN Stock Estimate TrendThe Zacks Consensus Estimate for Align Technology’s 2026 earnings per share (EPS) has remained constant at $11.31 in the past 30 days.

The Zacks Consensus Estimate for 2026 revenues is pegged at 4.17 billion. This suggests a 3.3% rise from the year-ago reported number.

Key PicksSome better-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Teleflex (TFX - Free Report) .

Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Globus Medical, sporting a Zacks Rank #1, has an earnings yield of 6.7% against the industry’s negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 27.3% against the industry’s 3.8% drop over the past year.

Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4% against the industry’s 3.7% decline over the past year.

Align Technology, Inc. (NASDAQ:ALGN – Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 2,293 call options on the stock. This represents an increase of 72% compared to the typical daily volume of 1,334 call options.

Analysts Set New Price Targets A number of analysts recently commented on the company. Needham & Company LLC reiterated a “hold” rating on shares of Align Technology in a report on Thursday, July 30th. UBS Group reiterated a “neutral” rating and set a $189.00 target price on shares of Align Technology in a research note on Thursday, July 23rd. BMO Capital Markets started coverage on shares of Align Technology in a report on Wednesday, July 8th. They issued an “outperform” rating and a $209.00 price target on the stock. Weiss Ratings upgraded shares of Align Technology from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday. Finally, Zacks Research lowered shares of Align Technology from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $206.36.

Check Out Our Latest Stock Report on Align Technology

Shares of NASDAQ ALGN opened at $153.49 on Wednesday. The stock has a fifty day simple moving average of $170.91 and a two-hundred day simple moving average of $173.44. Align Technology has a 1-year low of $122.00 and a 1-year high of $200.43. The firm has a market cap of $10.99 billion, a price-to-earnings ratio of 26.69, a price-to-earnings-growth ratio of 1.69 and a beta of 1.65. Align Technology (NASDAQ:ALGN – Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.62 by $0.02. Align Technology had a return on equity of 15.86% and a net margin of 9.99%.The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period last year, the business posted $2.49 earnings per share. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. Analysts forecast that Align Technology will post 9.38 EPS for the current year.

Institutional Investors Weigh In On Align Technology Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC lifted its holdings in Align Technology by 5.9% during the second quarter. NewEdge Advisors LLC now owns 2,826 shares of the medical equipment provider’s stock valued at $477,000 after purchasing an additional 157 shares during the last quarter. Squarepoint Ops LLC boosted its position in Align Technology by 101.1% during the second quarter. Squarepoint Ops LLC now owns 3,567 shares of the medical equipment provider’s stock worth $602,000 after purchasing an additional 1,793 shares during the period. Baird Financial Group Inc. increased its stake in shares of Align Technology by 11.2% in the second quarter. Baird Financial Group Inc. now owns 128,428 shares of the medical equipment provider’s stock worth $21,661,000 after purchasing an additional 12,945 shares in the last quarter. Beacon Investment Advisory Services Inc. increased its stake in shares of Align Technology by 14.7% in the second quarter. Beacon Investment Advisory Services Inc. now owns 3,081 shares of the medical equipment provider’s stock worth $520,000 after purchasing an additional 394 shares in the last quarter. Finally, Allworth Financial LP raised its position in shares of Align Technology by 3.1% in the second quarter. Allworth Financial LP now owns 3,393 shares of the medical equipment provider’s stock valued at $572,000 after purchasing an additional 101 shares during the period. 88.43% of the stock is currently owned by institutional investors.

About Align Technology (Get Free Report)

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.

Further Reading Five stocks we like better than Align Technology Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Canada Pension Plan Investment Board bought a new position in Align Technology, Inc. (NASDAQ:ALGN – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 26,510 shares of the medical equipment provider’s stock, valued at approximately $4,471,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Osterweis Capital Management Inc. purchased a new position in shares of Align Technology during the second quarter worth approximately $36,000. Parkman Healthcare Partners LLC bought a new position in shares of Align Technology during the 2nd quarter valued at $6,234,000. Legal & General Group Plc bought a new position in shares of Align Technology during the 2nd quarter valued at $22,542,000. The Manufacturers Life Insurance Company purchased a new position in Align Technology in the 2nd quarter worth $13,007,000. Finally, Vega Investment Solutions purchased a new position in Align Technology in the 2nd quarter worth $476,000. 88.43% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth Several analysts have issued reports on ALGN shares. Needham & Company LLC restated a “hold” rating on shares of Align Technology in a research report on Thursday, July 30th. BMO Capital Markets started coverage on Align Technology in a report on Wednesday, July 8th. They issued an “outperform” rating and a $209.00 price objective on the stock. Weiss Ratings lowered Align Technology from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd. UBS Group reissued a “neutral” rating and issued a $189.00 target price on shares of Align Technology in a research note on Thursday, July 23rd. Finally, Zacks Research cut Align Technology from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Align Technology currently has a consensus rating of “Moderate Buy” and a consensus price target of $206.36.

View Our Latest Research Report on Align Technology Align Technology Price Performance NASDAQ:ALGN opened at $157.58 on Monday. The firm has a market capitalization of $11.29 billion, a P/E ratio of 27.41, a P/E/G ratio of 1.67 and a beta of 1.65. The company has a fifty day moving average of $173.01 and a 200 day moving average of $175.03. Align Technology, Inc. has a 52 week low of $122.00 and a 52 week high of $200.43.

Align Technology (NASDAQ:ALGN – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.62 by $0.02. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.05 billion. Align Technology had a net margin of 9.99% and a return on equity of 15.86%. The company’s revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.49 EPS. As a group, analysts anticipate that Align Technology, Inc. will post 9.38 EPS for the current year.

Align Technology Company Profile (Free Report)

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.

Further Reading Five stocks we like better than Align Technology Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.

On August 17, 2026, Align Technology Inc
ALGN -5.6% 89

shares fell 5.6%, bringing the current price to $171.16. The stock has experienced a 52-week range of $122.00 to $200.44, reflecting volatility in the market.

GF Value™ verdict: Align Technology Inc is currently priced at $171.16, which is 23.6% below the GF Value™ estimate of $224.16, indicating it is undervalued.GF Score™ of 89/100 signals a strong company with solid overall fundamentals.Insider activity reveals that insiders sold $1.5M worth of shares over the past 12 months with no buying, suggesting cautious sentiment among insiders.Is ALGN Overvalued or Undervalued?According to GuruFocus, the GF Value™ estimate for Align Technology Inc is $224.16, which means the current price of $171.16 is significantly below this intrinsic value. This 23.6% margin of safety suggests an opportunity for investors looking for undervalued stocks. The GF Valuation label indicates that the stock is modestly undervalued, based on a comprehensive analysis of historical trading multiples, business performance, and future growth estimates.

While the undervaluation presents a potential opportunity, it is essential to consider market conditions and company performance that may affect future valuations. The stock's recent decline could be a response to broader market trends or specific company news that has yet to be fully assessed by the market.

How Does ALGN's Valuation Compare to Its History?MetricCurrentHistoricalP/E (TTM)29.8x38.5xForward P/E15.1xN/AAlign Technology's current P/E (TTM) of 29.8x is significantly lower than its 5-year median P/E of 38.5x, indicating that the stock is trading at a discount compared to its historical valuation. This aligns with the GF Value™ verdict, reinforcing the notion that ALGN is undervalued in the current market conditions.

What Does ALGN's GF Score™ Tell Us?The GF Score™ is a composite rating that evaluates a company's financial strength, profitability, growth, valuation, and momentum, helping investors understand the overall quality of the investment. Align Technology's GF Score™ of 89/100 reflects strong fundamentals, with its most notable strengths in profitability (9/10) and valuation (8/10), while its growth rank (7/10) and financial strength (7/10) are solid but comparatively weaker.

MetricRatingGF Score™89Financial Strength7/10Profitability9/10Growth7/10Valuation8/10Momentum8/10The strong GF Score™ indicates that Align Technology is performing well across multiple metrics, particularly in profitability, which could attract potential investors. However, the company should focus on improving its financial strength and growth ranks to enhance its overall appeal further.

What Are Gurus and Insiders Doing with ALGN?Currently, six gurus hold shares of Align Technology Inc, with four increasing their positions and three trimming theirs in recent quarters. This mixed activity suggests a level of confidence among some institutional investors while also reflecting caution among others. The presence of multiple gurus indicates a level of interest and support for the stock, which can be a positive signal for potential investors.

On the insider front, the sale of $1.5M in shares over the past 12 months, without any buying activity, may raise concerns regarding the outlook from those closest to the company. This selling pattern could suggest that insiders are not optimistic about the near-term performance of the stock, which is an important consideration for any investment decision.

What This Means for InvestorsBased on the GF Value™ analysis, Align Technology Inc appears to be undervalued at its current price of $171.16, with a substantial margin of safety identified. However, the insider selling activity and mixed signals from guru ownership introduce a level of caution. It is essential for investors to weigh these factors carefully while considering Align Technology's potential. For further information, readers can visit the Align Technology Inc
ALGN -5.6% 89

stock page and explore the GF Value™ page for a deeper analysis.

Frequently Asked QuestionsWhat is ALGN's GF Score™?

Align Technology Inc has a GF Score™ of 89/100, indicating strong overall fundamentals and a solid position within its industry.

Is ALGN overvalued or undervalued?

According to the GF Value™ estimate, ALGN is currently undervalued, with a price that is 23.6% below its intrinsic value of $224.16.

What is ALGN's P/E ratio?

Align Technology's P/E (TTM) ratio is 29.8x, which is significantly below its 5-year median P/E of 38.5x, suggesting that the stock is undervalued compared to its historical performance.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Key Takeaways Align recorded a $37.5M U.K. VAT liability after the tribunal reversed the prior tax exemption.Align will charge 20% VAT on certain U.K. products from Sept. 7 while keeping list prices unchanged. ALGN expects about 6% Clear Aligner volume growth as international demand helps offset U.K. uncertainty. Align Technology (ALGN - Free Report) is dealing with a new U.K. tax issue in 2026. A July Upper Tribunal decision overturned the prior value-added tax exemption for clear aligners, adding a fresh earnings and pricing variable.

The ruling arrives as international Clear Aligner demand remains healthy but foreign exchange, softer retail demand and scanner mix continue to complicate the margin picture.

ALGN Absorbs a $37.5 Million U.K. VAT LiabilityAlign recorded an estimated $37.5 million liability, including interest, after the U.K. Upper Tribunal reversed the earlier VAT-exemption ruling. The charge makes the dispute an immediate earnings matter rather than a legal issue with only future consequences.

The accrual also contributed to higher second-quarter operating expenses. Those expenses rose 10.7% year over year to $603.4 million, with the U.K. VAT accrual and higher employee compensation among the main drivers.

In the past year, ALHC shares have risen 25.1% compared with the industry’s 21.5% growth. 

Image Source: Zacks Investment Research

Align Will Add 20% VAT Without Raising List PricesFrom Sept. 7, 2026, Align plans to charge 20% VAT on applicable U.K. Invisalign aligners and Vivera retainers while keeping list prices unchanged. That changes the economics of an established product line without changing published list prices.

The development adds another pricing variable in the U.K. Align already expects 2026 Clear Aligner average selling prices to be flat to slightly down from 2025, reflecting broader mix pressure across countries and products.

Per the Zacks Consensus Estimate, the company’s 2026 revenues are pegged at $4.17 billion, indicating 3.3% year over year growth. 

Image Source: Zacks Investment Research

ALGN’s Appeal Keeps the Final Cost UncertainAlign plans to appeal the tribunal decision, so the final financial outcome remains unresolved. The $37.5 million liability is already recorded, but the longer-term cost and operating consequences will depend on how the appeal process develops.

That distinction matters for investors. The current accrual is visible in 2026 results, while the durability of the VAT treatment remains uncertain and could continue to influence how Align manages the U.K. business.

Align Faces the VAT Issue Amid Other Margin PressuresForeign exchange was already weighing on profitability before the VAT issue became more prominent. In the second quarter, currency movements reduced gross margin by about 0.8 percentage points and operating margin by about 1.4 points year over year.

The broader dental market provides useful context. DENTSPLY SIRONA Inc. (XRAY - Free Report) manufactures professional dental products and technologies across equipment, consumables and specialty products. Henry Schein, Inc. (HSIC - Free Report) supplies office-based dental practitioners with merchandise, equipment and technology solutions, making both relevant industry reference points even though Align’s VAT dispute is company-specific.

ALGN’s Global Growth Helps Offset the U.K. RiskInternational Clear Aligner growth remains a counterweight. Second-quarter volume increased at double-digit rates in both EMEA and APAC, while Latin America delivered record second-quarter shipments.

That geographic momentum supports Align’s broader 2026 volume outlook. Management now expects Clear Aligner volume growth of approximately 6%, leaving investors to weigh expanding international demand against the incremental cost and uncertainty concentrated in the U.K.

Align’s Ratings Point to Caution Around the EventThe VAT ruling has already created a measurable charge, while the appeal leaves the longer-term impact unsettled. For 2026, the issue adds to currency and mix pressures rather than standing alone as the only driver of Align’s earnings outlook.

ALGN currently carries a Zacks Rank #3 (Hold), with a Value Score of B, Growth Score of B, VGM Score of B and Momentum Score of F. The B scores are favorable within the Style Score framework, but the F Momentum Score signals weak timing support. That combination is consistent with monitoring the appeal and operating impact rather than treating the VAT ruling by itself as a decisive bullish or bearish catalyst.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign System of clear

Posted by Defense World Staff on Aug 10th, 2026

Contravisory Investment Management Inc. acquired a new stake in Align Technology, Inc. (NASDAQ:ALGN – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 6,557 shares of the medical equipment provider’s stock, valued at approximately $1,106,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ALGN. Blue Trust Inc. boosted its holdings in Align Technology by 77.5% in the first quarter. Blue Trust Inc. now owns 158 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 69 shares in the last quarter. Sunbelt Securities Inc. raised its holdings in Align Technology by 222.4% during the fourth quarter. Sunbelt Securities Inc. now owns 158 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 109 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new stake in shares of Align Technology during the 2nd quarter worth approximately $36,000. Tobam acquired a new position in shares of Align Technology in the 4th quarter valued at $30,000. Finally, Hollencrest Capital Management acquired a new position in shares of Align Technology in the 1st quarter valued at $34,000. Institutional investors and hedge funds own 88.43% of the company’s stock.

Align Technology Price Performance ALGN stock opened at $173.66 on Monday. The company has a market cap of $12.44 billion, a price-to-earnings ratio of 30.20, a price-to-earnings-growth ratio of 1.85 and a beta of 1.65. The company has a fifty day moving average price of $175.06 and a 200 day moving average price of $175.30. Align Technology, Inc. has a 12 month low of $122.00 and a 12 month high of $200.43.

Align Technology (NASDAQ:ALGN – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.02. The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.05 billion. Align Technology had a net margin of 9.99% and a return on equity of 15.86%. Align Technology’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period last year, the firm posted $2.49 EPS. As a group, analysts anticipate that Align Technology, Inc. will post 9.38 earnings per share for the current year.

Align Technology declared that its Board of Directors has initiated a stock buyback plan on Wednesday, April 29th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the medical equipment provider to buy up to 1.6% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth Several equities research analysts recently commented on ALGN shares. Needham & Company LLC reiterated a “hold” rating on shares of Align Technology in a research note on Thursday, July 30th. Wall Street Zen downgraded shares of Align Technology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 1st. Citigroup started coverage on Align Technology in a report on Wednesday, April 15th. They issued a “buy” rating and a $240.00 target price for the company. Morgan Stanley upped their target price on Align Technology from $169.00 to $188.00 and gave the company an “equal weight” rating in a research report on Friday, April 24th. Finally, Evercore upped their target price on Align Technology from $200.00 to $220.00 in a research report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $206.36.

Read Our Latest Report on Align Technology

About Align Technology (Free Report)

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.

Featured Articles Five stocks we like better than Align Technology Albemarle’s Blowout Quarter Shows Why Lithium Still Matters Can DICK’S Turn Foot Locker Into a Winner? Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War Want to see what other hedge funds are holding ALGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Align Technology, Inc. (NASDAQ:ALGN – Free Report).

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia State Teachers Retirement System Boosts Position in Steven Madden, Ltd. $SHOO

NEXT HEADLINE »Echostar CORP $ECHO Shares Purchased by Contravisory Investment Management Inc.

Align Technology delivers record revenue, volume, and operating margins, yet trades near five-year valuation lows despite structural business improvements. Competitive pressures have eased post-SmileDirectClub exit, with ALGN retaining dominant market share and shifting growth toward international and DSO channels. Operating margins are expanding, management continues to raise guidance, and a robust buyback program is underway, supported by strong free cash flow.

Posted by Defense World Staff on Aug 3rd, 2026

California State Teachers Retirement System grew its position in shares of Align Technology, Inc. (NASDAQ:ALGN – Free Report) by 21.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 79,293 shares of the medical equipment provider’s stock after buying an additional 13,867 shares during the period. California State Teachers Retirement System owned approximately 0.11% of Align Technology worth $13,593,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of ALGN. Capital International Investors grew its stake in shares of Align Technology by 52.2% in the fourth quarter. Capital International Investors now owns 4,643,221 shares of the medical equipment provider’s stock valued at $725,039,000 after acquiring an additional 1,592,848 shares in the last quarter. Ruane Cunniff & Goldfarb L.P. bought a new position in Align Technology during the fourth quarter worth about $190,899,000. Norges Bank acquired a new stake in Align Technology in the 4th quarter worth about $155,556,000. Assenagon Asset Management S.A. raised its stake in Align Technology by 413.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 989,388 shares of the medical equipment provider’s stock worth $169,611,000 after purchasing an additional 796,529 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Align Technology by 247.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,005,413 shares of the medical equipment provider’s stock valued at $156,995,000 after purchasing an additional 715,919 shares during the period. Institutional investors and hedge funds own 88.43% of the company’s stock.

Trending Headlines about Align Technology Here are the key news stories impacting Align Technology this week:

Positive Sentiment: Q2 results exceeded expectations. Align reported adjusted earnings of $2.64 per share and revenue of approximately $1.06 billion, topping consensus estimates. Revenue increased 4.3% year over year, while record Clear Aligner shipments and improved non-GAAP margins supported profitability. Align Technology Q2 Earnings and Revenues Top Estimates Positive Sentiment: Digital orthodontics remains a growth focus. Management highlighted expanding digital workflows, connected orthodontic tools and long-term opportunities for Invisalign, iTero scanners and exocad software. The company’s 2026 outlook was reaffirmed, while an orthodontic summit showcased its product and technology strategy. ALGN Q2 Earnings Call Highlights Digital Growth Push Positive Sentiment: Board changes could improve shareholder value. Following discussions with Elliott Investment Management, Align plans to add three independent directors and conduct an operational review. The initiatives may increase accountability, improve execution and identify opportunities to enhance returns. Align Technology to Overhaul Board Following Engagement with Elliott Neutral Sentiment: Valuation is viewed as more attractive after the pullback. Some analysts see ALGN as reasonably valued, but believe the stock needs faster growth to generate sustained upside. Align Technology: Attractively Valued, But Growth Still Needs To Pick Up Negative Sentiment: Near-term guidance and execution remain concerns. Third-quarter revenue guidance of roughly $1.0 billion was described as slightly below or around expectations, limiting the benefit of the earnings beat. Negative Sentiment: Systems weakness is capping upside. Analysts noted softer scanner and systems performance, along with pricing pressure, despite strong Clear Aligner volumes. Needham maintained a Hold rating. Align Technology Hold Rating Maintained Negative Sentiment: Growth is still relatively modest. Investors may remain cautious because revenue growth has not yet accelerated enough to justify a more bullish outlook, even with improving margins and record aligner shipments. Align Technology Price Performance ALGN stock opened at $169.16 on Monday. Align Technology, Inc. has a 12 month low of $122.00 and a 12 month high of $200.43. The firm has a market cap of $12.12 billion, a P/E ratio of 29.42, a P/E/G ratio of 1.78 and a beta of 1.65. The company’s 50-day moving average price is $174.55 and its two-hundred day moving average price is $175.23.

Align Technology (NASDAQ:ALGN – Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $2.64 EPS for the quarter, beating the consensus estimate of $2.62 by $0.02. Align Technology had a net margin of 9.99% and a return on equity of 15.86%. The company had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.05 billion. During the same period in the previous year, the company earned $2.49 EPS. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. Equities analysts predict that Align Technology, Inc. will post 9.48 EPS for the current year.

Align Technology announced that its board has authorized a stock repurchase program on Wednesday, April 29th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the medical equipment provider to repurchase up to 1.6% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets ALGN has been the topic of a number of analyst reports. UBS Group restated a “neutral” rating and set a $189.00 target price on shares of Align Technology in a research report on Thursday, July 23rd. BMO Capital Markets initiated coverage on shares of Align Technology in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $209.00 price target for the company. Evercore boosted their price target on Align Technology from $200.00 to $220.00 in a research note on Thursday, April 30th. Morgan Stanley increased their price target on Align Technology from $169.00 to $188.00 and gave the stock an “equal weight” rating in a research report on Friday, April 24th. Finally, Wall Street Zen lowered Align Technology from a “strong-buy” rating to a “buy” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $206.36.

Check Out Our Latest Stock Analysis on Align Technology

About Align Technology (Free Report)

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.

Read More Five stocks we like better than Align Technology 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story AbbVie Quietly Solved Its Biggest Problem—Now What? Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade Strategy’s Structural Strength: Hidden in a $8 Billion Illusion

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEFinancial Solutions Advisory Group Inc. Makes New Investment in Caterpillar Inc. $CAT

Align Technology delivered record Q2 revenue and clear aligner volumes, with robust international growth offsetting North American stagnation. ALGN's strategy centers on expanding its digital dentistry platform, leveraging financing, lower-cost products, and ecosystem growth to drive recurring revenue. Valuation at $173 per share (15–16x forward earnings) is attractive for a market leader with high margins, net cash, and ongoing share buybacks.

Key Takeaways Align Technology reported record 691,785 clear aligner shipments, up 7.4% year over year.ALGN expanded scanner adoption as flexible models grew the digital platform and installed base.Align focused on margin gains, buybacks and strategic reviews while maintaining 2026 outlook. Align Technology, Inc. (ALGN - Free Report) used its second-quarter 2026 earnings call to emphasize continued Invisalign momentum, expanding digital workflows and efforts to improve operating leverage. Management highlighted record clear aligner volumes while acknowledging near-term pressure from scanner pricing changes and flexible purchasing models.

The discussion centered on balancing current revenue mix challenges with longer-term platform expansion. Executives also addressed strategic reviews, capital allocation and investor questions around North America demand trends.

ALGN Advances Clear Aligner MomentumCEO Joseph Hogan said growth remained broad-based across geographies, customer channels and patient segments. Clear Aligner shipments reached a record 691,785 cases in the quarter, up 7.4% year over year, supported by international expansion and stable North American performance.

Hogan noted that adoption continued among orthodontists, general practitioners and dental support organizations. He highlighted investments in patient financing, clinical support programs and doctor subscription offerings as tools supporting utilization and patient conversion.

The company also pointed to continued strength among younger patients. Teen and growing patient treatment starts increased 7.2% year over year to 240,000 Invisalign cases, supported by adoption of newer treatment solutions.

Align Expands Digital Platform StrategyAlign Technology’s scanner strategy remained a major discussion point during the call. Management said Systems and Services revenues declined 10.8% year over year to $185.3 million due to lower scanner average selling prices and greater use of leasing and rental models.

CFO John Morici explained that the shift toward flexible acquisition options is intentional. The company is accepting lower upfront revenues to increase scanner adoption and expand future treatment opportunities through its digital platform.

Management highlighted that scanner placements to new doctors reached a record level, while the active scanner installed base grew approximately 11% year over year. The company said these trends support broader digital workflow adoption.

ALGN Focuses on Margins and CashThe company reported second-quarter revenues of $1.06 billion, up 4.3% year over year, beating the consensus mark of $1.05 billion. Non-GAAP adjusted EPS increased to $2.64 from $2.49 a year earlier, surpassing the Zacks Consensus Estimate of $2.56.

Morici said margin improvements were supported by operational efficiencies, higher Clear Aligner average selling prices and manufacturing improvements. Non-GAAP operating margin reached 22.9%, up from 21.3% in the prior-year period.

ALGN ended the quarter with $1.1 billion in cash and repurchased approximately 393,400 shares for about $67 million. Management increased its 2026 repurchase expectation to $400 million to $500 million.

Align Adjusts Outlook for 2026Management maintained its expectation for 2026 revenue growth of 3% to 4% year over year. Clear Aligner volume growth is expected to be approximately 6%, while Systems and Services revenues are projected to decline 6% to 8%.

For the third quarter, Align expects revenues of $1.0 billion to $1.02 billion. Management expects continued scanner mix pressure and seasonal factors to affect Systems and Services results.

The company also expects restructuring and other one-time charges to affect third-quarter margins. Full-year non-GAAP operating margin is expected to improve by about 100 basis points from the 2025 levels.

ALGN Addresses Investor QuestionsA Leerink Partners analyst asked about confidence in maintaining Invisalign case growth despite consumer uncertainty. Hogan pointed to the company’s global mix, including strength in APAC, Europe and Latin America, as a factor supporting resilience.

A Stifel analyst questioned whether North American independent practices were improving and whether financing initiatives could help demand. Hogan said the company remains focused on product innovation, affordability programs and expanded treatment options.

Analysts also pressed management on scanner revenue pressure. Executives reiterated that lower upfront scanner economics are part of a broader strategy to expand the installed base and create future treatment revenue opportunities.

Align Maintains Long-Term Growth FocusManagement emphasized that strategic priorities remain centered on digital orthodontics, restorative dentistry and expanding patient access. Hogan said the company is continuing efforts to improve execution, strengthen innovation and increase operating leverage.

Align also announced plans to add independent directors and conduct a strategic and operating model review following discussions with Elliott Management. The company said the review is intended to improve commercial execution and organizational effectiveness.

The company’s next phase will depend on balancing near-term scanner revenue pressure with long-term digital platform expansion. Management continues to focus on adoption, utilization and margin improvement.

ALGN’s Zacks Rank and Style Score SignalsALGN carries a Zacks Rank #4 (Sell), indicating that earnings estimate revision trends currently point to weaker potential performance relative to higher-ranked stocks. The Zacks Rank can change as analysts update earnings expectations following new financial results.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The stock has a Value Score of C, Growth Score of A, Momentum Score of D and VGM Score of B. Zacks Style Scores are designed to complement the Zacks Rank by evaluating characteristics such as value, growth and momentum, with stronger scores generally indicating more favorable traits.

Align Technology, Inc. (ALGN) Q2 2026 Earnings Call Transcript

Why These 3 Tech Stocks Could Be the Best Opportunities You're OverlookingAlign Technology NASDAQ: ALGN reported record second-quarter revenue of $1.06 billion, up 4.3% from a year earlier, as record clear aligner volumes and higher revenue in that business offset continued weakness in its systems and services segment.

Chief Executive Officer Joe Hogan said second-quarter results were supported by clear aligner shipments of 692,000 cases, a 7.4% year-over-year increase. Clear aligner revenue rose 8.2% to $870.9 million, while the company’s average per-case shipment price increased 0.8% to $1,260.

Get Align Technology alerts:

Buy the Dip? These Earnings Misses Offer Long-Term Upside“Q2 2026 revenues and clear aligner volumes were in line with our outlook, while clear aligner ASPs and non-GAAP operating margin of 22.9% exceeded our expectations,” Hogan said.

Clear aligner growth led by international markets Align said clear aligner volume growth was driven by double-digit expansion in Asia-Pacific, Europe, the Middle East and Africa, and Latin America, while North American performance was relatively stable. The company cited continued adoption among orthodontists, general-practice dentists and dental service organizations, or DSOs.

MarketBeat Week in Review: 12/25 - 12/29Record 89,200 doctors submitted Invisalign cases in the quarter, a 3.4% increase from a year earlier, while doctor utilization rose 3.8%. Shipments to orthodontists increased 7.8%, and shipments to general-practice dentists rose 6.6%.

Teen and growing-patient treatment starts increased 7.2% to 240,000 Invisalign cases, with growth led by China, Japan, Turkey, India and Brazil. Hogan said adoption of Invisalign First, the Invisalign Palatal Expander and Invisalign mandibular advancement with occlusal blocks continued to strengthen doctor confidence in the company’s offerings for younger patients.

During the question-and-answer session, Hogan described North American conditions as stable but uneven by region. He said growth in the DSO channel has helped offset weaker retail demand, while the company is seeking to improve North American retail performance through financing, clinical support, education and workflow initiatives.

Management said it is not assuming an improvement in the broader macroeconomic environment in its outlook. Instead, it pointed to patient financing, doctor subscription programs, lower-cost offerings and product innovation as drivers of future case volumes.

Scanner strategy weighs on reported systems revenue Systems and services revenue declined 10.8% year over year to $185.3 million. The segment includes iTero imaging systems, exocad CAD/CAM software and Align X-Ray Insight software.

Chief Financial Officer John Morici said the decline reflected lower scanner average selling prices, lower scanner wand sales and a strategic shift toward lower-cost scanner configurations, certified pre-owned units, leases and rentals. These options produce less upfront revenue than traditional scanner purchases but are intended to broaden access to the company’s digital workflow platform.

Despite the revenue decline, placements to new doctors reached a record and increased at a double-digit rate year over year. Align’s active scanner install base grew about 11%, while more than 12.4 million restorative, wellness and orthodontic scans were completed during the quarter, up 16%.

Hogan said the company views the lower upfront economics as a deliberate trade-off. Align expects a larger installed base to support recurring revenue and increase opportunities for Invisalign and restorative treatment adoption over time.

Exocad revenue grew at a double-digit rate during the quarter. The company also introduced exocad ART, or Advanced Restorative Treatment, which combines tooth alignment and restorative treatment planning within exocad software.

Margins, cash flow and shareholder returns Align’s GAAP operating income was $154 million, representing an operating margin of 14.6%, down about 1.5 percentage points from the prior year. GAAP diluted earnings per share were $1.51, down $0.20 year over year.

On a non-GAAP basis, operating margin rose 1.6 percentage points to 22.9%, and diluted earnings per share increased 6% to $2.64. The company said its non-GAAP results exclude items including stock-based compensation, certain legal settlements and contingencies, restructuring charges, and amortization of acquired intangible assets.

Overall gross margin was 71.7%, up 1.8 percentage points year over year, driven by operational efficiencies, a tariff refund and higher clear aligner average selling prices. Morici said lower refinement rates, improved treatment predictability and manufacturing throughput have supported margin expansion.

Cash and cash equivalents totaled $1.10 billion at June 30. The company generated $192.8 million in operating cash flow and $157.1 million in free cash flow during the quarter. Align repurchased about 393,400 shares for $67 million during the period.

The company now plans to repurchase approximately $400 million to $500 million of stock during 2026, including purchases under its previously announced $200 million open-market plan.

VAT charge, strategic review and outlook Align recorded an estimated $37.5 million liability, including interest, following a U.K. Upper Tribunal ruling that clear aligners do not qualify as VAT-exempt dental prostheses. The company said it will begin including 20% U.K. VAT on applicable Invisalign aligners and Vivera retainers on invoices beginning Sept. 7, while holding its list prices unchanged. Align intends to appeal the ruling.

The company also announced initiatives following discussions with Elliott Management, including plans to add three independent directors and conduct a comprehensive strategic and operating-model review with a global consulting firm. Hogan said the review will examine commercial execution, organizational effectiveness, scalability and resource optimization.

For the third quarter, Align forecast revenue of $1 billion to $1.02 billion. It expects clear aligner volumes to rise by the mid-single digits year over year, while clear aligner average selling prices are expected to decline sequentially due to geographic mix and foreign exchange effects.

Align expects third-quarter non-GAAP operating margin of approximately 24%, while GAAP operating margin is projected at 13.5% to 15%, reflecting anticipated restructuring, accelerated depreciation and other one-time charges.

For full-year 2026, the company maintained its forecast for revenue growth of 3% to 4%. It now expects clear aligner volume growth of approximately 6%, clear aligner average selling prices to be flat to slightly down, and systems and services revenue to decline 6% to 8%.

Morici said Align is not issuing formal 2027 guidance but is targeting at least 100 basis points of year-over-year improvement in both GAAP and non-GAAP operating margin next year, following its expected approximately 100-basis-point non-GAAP margin improvement in 2026.

About Align Technology (NASDAQ:ALGN)Align Technology, Inc NASDAQ: ALGN pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company's signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Align Technology Right Now?Before you consider Align Technology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Align Technology wasn't on the list.

While Align Technology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

LAS VEGAS & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from its 2026 Invisalign® Ortho Summit, held July 23–26, 2026 in Las Vegas. The Summit brought together more than 500 orthodontists and practice team members for an.

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the second quarter ("Q2'26"). Q2'26 total revenues were $1,056.2 million, up 1.5% sequentially and up 4.3% year-over-year. Q2'26 total revenues were unfavorably imp.

CompaniesJuly 29 (Reuters) - Align Technology (ALGN.O), opens new tab said on Wednesday it will add three new ​independent directors to its board and launch ‌a review of its operations, following talks with activist investor Elliott Investment Management.

Shares of the company ​were down 4.5% in extended trading.

Learn about the latest breakthroughs in AI and tech with the Reuters Artificial Intelligencer newsletter. Sign up here.

Align ​has hired a leading global consulting ⁠firm to conduct a comprehensive review of ​its operations and business model. The company ​said the review will focus on improving revenue growth and boosting profit margins.

The changes follow discussions ​with Elliott, one of Align's largest shareholders.

Marc ​Steinberg, a partner at Elliott, in a statement called ‌Align ⁠a market leader with significant growth potential. "We believe the board enhancements and other actions announced today are important steps toward ​delivering on ​this opportunity," ⁠he said.

The medical device company, best known for making Invisalign ​clear teeth aligners, said it raised ​its ⁠share buyback target for the year to between $400 million and $500 million, up from the ⁠earlier ​target of $200 million, citing ​confidence in its long-term value.

Reporting by Padmanabhan Ananthan in Bengaluru; ​Editing by Shailesh Kuber and Sahal Muhammed

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Posted by Defense World Staff on Jul 26th, 2026

Shares of Align Technology, Inc. (NASDAQ:ALGN – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $206.3571.

ALGN has been the topic of several research analyst reports. Leerink Partners raised their price target on Align Technology from $225.00 to $230.00 in a research report on Thursday, April 30th. Zacks Research cut Align Technology from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 16th. Evercore increased their target price on Align Technology from $200.00 to $220.00 in a research note on Thursday, April 30th. Wall Street Zen raised Align Technology from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 4th. Finally, Citigroup began coverage on Align Technology in a research report on Wednesday, April 15th. They issued a “buy” rating and a $240.00 price target on the stock.

View Our Latest Stock Analysis on ALGN

Hedge Funds Weigh In On Align Technology A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bessemer Group Inc. boosted its holdings in Align Technology by 37.2% in the 1st quarter. Bessemer Group Inc. now owns 247 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 67 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. grew its position in Align Technology by 3.7% in the 4th quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 1,896 shares of the medical equipment provider’s stock worth $296,000 after purchasing an additional 68 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Align Technology by 77.5% during the 1st quarter. Blue Trust Inc. now owns 158 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 69 shares during the period. Comerica Bank increased its holdings in shares of Align Technology by 0.6% during the 4th quarter. Comerica Bank now owns 13,656 shares of the medical equipment provider’s stock worth $2,132,000 after purchasing an additional 76 shares during the period. Finally, First Bank & Trust raised its position in shares of Align Technology by 5.0% during the second quarter. First Bank & Trust now owns 1,599 shares of the medical equipment provider’s stock valued at $270,000 after buying an additional 76 shares during the last quarter. Institutional investors own 88.43% of the company’s stock.

Align Technology Trading Down 0.7% NASDAQ:ALGN opened at $167.01 on Thursday. Align Technology has a 1 year low of $122.00 and a 1 year high of $208.30. The firm’s fifty day simple moving average is $173.31 and its 200 day simple moving average is $175.01. The firm has a market capitalization of $11.96 billion, a PE ratio of 28.02, a PEG ratio of 1.71 and a beta of 1.67.

Align Technology (NASDAQ:ALGN – Get Free Report) last announced its earnings results on Wednesday, April 29th. The medical equipment provider reported $2.58 EPS for the quarter, topping the consensus estimate of $2.26 by $0.32. Align Technology had a net margin of 10.50% and a return on equity of 15.82%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the firm posted $2.13 EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, analysts anticipate that Align Technology will post 9.48 EPS for the current fiscal year.

Align Technology announced that its board has authorized a stock repurchase plan on Wednesday, April 29th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the medical equipment provider to repurchase up to 1.6% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

About Align Technology (Get Free Report)

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.

Featured Stories Five stocks we like better than Align Technology Telecom Earnings Reveal a Sector That Finally Looks Healthier Defense Earnings Show Readiness Now and Modernization Ahead Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off MarketBeat Week in Review – 07/20- 07/24

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBrokerages Set Graphic Packaging Holding Company (NYSE:GPK) Price Target at $11.03

NEXT HEADLINE »Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $24.25 Consensus Target Price from Analysts

TEMPE, Ariz & SAN JOSE, Calif.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today introduced new innovations across its integrated Align™ Digital Platform*, designed to help doctors visualize, plan, and treat with greater confidence and predictability. Throug.